Efficacy and tolerability of neoretin discrom control serum in the treatment of melasma

Abstract

Objectives: To evaluate the efficacy and safety of Neoretin Discrom Control Serum for the treatment
of melasma.
Methods: A clinical trial in 36 melasma patients treated with Neoretin Discrom Control Serum for
4 months. Patients were re-examined at weeks 4, 8, 12, 16; Facial pictures by digital camera were taken
and were evaluated the improvement of melasma on the MASI scale, on dermoscopy, the change in
Melanin index through the Mexameter, clinical side effects and patient satisfaction during and after
treatment was noted.
Results: Melasma treatment with Neoretin Discrom Control Serum resulted in a 64% reduction
in MASI (from 15.23 to 5.52) after 4 months of treatment. Melanin index measured by Mexameter
also decreased after 4 months with a reduction rate of 30.4%. The most common undesirable effect
is a stinging sensation (52.8%). Other side effects include itching, burning, redness, dry skin, scaling,
acne, and hyperpigmentation. Side effects were encountered mainly in the first month and were
mild-moderate. No serious side effects and no systemic side effects were detected. After 4 months
of treatment, the patient’s self-rated melasma lesions improved by 46%, with an average satisfaction
score of 7.8/10.
Conclusion: Neoretin Discrom Control Serum proved to be an effective and safe product for the
treatment of melasma. It should be combined with moisturizers and skin-soothing creams to minimize
unwanted effects.

Received: 15/05/2022
Revised: 16/06/2022
Accepted:  20/06/2022